4,4-Disubstituted Piperidine High-Affinity NK1 Antagonists: Structure−Activity Relationships and in Vivo Activity
Citations Over Time
Abstract
Previously reported studies from these laboratories described the design of a novel series of high-affinity NK1 antagonists based on the 4,4-disubstituted piperidine ring system. Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3, 5-bis(trifluoromethyl)benzyl ether, 12 (hNK1 IC50 = 0.95 nM). Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives. Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).
Related Papers
- → Comparison of an in vitro method and an in vivo method of Giardia excystation(1992)23 cited
- → IN VITRO SPECIFICITY AND IN VIVO ACTIVITY OF ANTIMACROPHAGE SERUM(1974)4 cited
- → Actin Organization as an in Vitro Assay for Tumorigenicity(1982)2 cited
- [Pharmacodynamic study of the in vitro clonogenic assay--with reference to dose levels].(1988)
- The release of the marked insulin J125 from ointment in vitro and in vivo.(1993)